

Cancer Prevention and Research Institute of Texas
Quarterly Financial Report
As of August 31, 2024

Indirect Administration (B.1.1.)

	2024 Appropriated	2024 Budgeted	% of Total Budget	Actual Expenditures & Grant Encumbrances (FYTD)	Remaining Budget	Percent Expended	Estimated Expenditures (YTD)	Lapse/Overspent
1001 Salaries and Wages	\$ 1,847,425	\$ 1,930,411		\$ 1,930,411	(0)	100%	\$ 1,930,411	\$ (0)
1002 Other Personnel Costs	38,785	107,840		107,840	0	100%	107,840	0
2001 Professional Fees and Services	1,808,662	1,980,859		1,029,220	951,639	52%	1,029,220	951,639
2003 Consumable Supplies	24,000	24,000		6,600	17,400	28%	6,600	17,400
2004 Utilities	58,600	58,600		41,500	17,100	71%	41,500	17,100
2005 Travel	45,000	69,526		69,526	0	100%	69,526	0
2006 Rent-Building	11,000	33,112		33,112	0	0%	33,112	0
2007 Rent-Machine and Other	32,172	32,172		7,022	25,150	22%	7,022	25,150
2009 Other Operating Expenses	1,045,249	1,783,611		1,460,313	323,297	82%	1,460,313	323,297
Subtotal - Indirect Administration (B.1.1.)	\$ 4,910,893	\$ 6,020,132	2.02%	\$ 4,685,546	\$ 1,334,586	78%	\$ 4,685,546	\$ 1,334,586

Grant Review and Award Operations (A.1.3.)

	2024 Appropriated	2024 Budgeted	% of Total Budget	Actual Expenditures & Grant Encumbrances (FYTD)	Remaining Budget	Percent Expended	Estimated Expenditures (YTD)	Lapse/Overspent
1001 Salaries and Wages	\$ 3,505,873	4,151,525		\$ 4,424,275	\$ (272,751)	107%	\$ 4,424,275	\$ (272,751)
1002 Other Personnel Costs	45,000	139,654		139,654	0	0%	139,654	0
2001 Professional Fees and Services	12,419,373	11,761,810		11,566,807	195,003	98%	11,566,807	195,003
2003 Consumable Supplies	-	-		-	-	0%	-	-
2004 Utilities	12,000	12,000		-	12,000	0%	-	12,000
2005 Travel	45,000	45,000		30,143	14,857	67%	30,143	14,857
2009 Other Operating Expenses	71,649	310,866		310,866	0	100%	310,866	0
Subtotal - Grant Operations (A.1.3.)	\$ 16,098,895	\$ 16,420,855	5.51%	\$ 16,471,745	\$ (50,890)	100%	\$ 16,471,745	\$ (50,890)

Grants

	2024 Appropriated	2024 Budgeted	% of Total Budget	Actual Expenditures & Grant Encumbrances (FYTD)	Remaining Budget	Percent Expended	Estimated Expenditures (YTD)	Lapse/Overspent
4000 Grants - Prevention (A.1.2)	\$ 27,671,780	\$ 25,968,624		\$ 25,902,480	\$ 66,144	100%	\$ 25,902,480	\$ 66,144
4000 Grants - Research (A.1.1.)	248,251,400	\$ 249,522,349		135,886,309	\$ 113,636,040	54%	135,886,309	113,636,040
Subtotal - Grants	\$ 275,923,180	\$ 275,490,973	92.47%	\$ 161,788,789	\$ 113,702,184	59%	\$ 161,788,789	\$ 113,702,184
Grand Totals	\$ 296,932,968	\$ 297,931,960	100.00%	\$ 182,946,079	\$ 114,985,880	61%	\$ 182,946,079	\$ 114,985,880

**Cancer Prevention and Research Institute of Texas
Cancer Prevention and Research Institute Fund Account - 5136
As of August 31, 2024**

	8/01/2024- 8/31/2024	AY 24 Year to Date as of 8/31/2024
Beginning Balance : 9/01/2023		\$ 600,506
Increases:		
(1)	\$ -	\$ -
(2)	-	
Total Increases	\$ -	\$ 600,506.00
Reductions:		
Expenditures - Appropriated	\$ -	\$ -
	\$ -	\$ -
	\$ -	\$ -
Total Reductions	\$ -	\$ -
Ending Balance: 8/31/2024		\$ 600,506.00

Note: (1) The Institute received a settlement from the Texas Cancer Coalition (TCC). This amount represents the final distribution and transfer of all funds (\$303,877) from the TCC which ceased operations in May 2013. These funds are in the State Treasury but are not appropriated to CPRIT. The beginning balance reflects the transfer of all TCC funds.

**Cancer Prevention and Research Institute of Texas
License Plate Trust Fund Account - 0802
As of August 31, 2024**

	8/01/2024- 8/31/2024	AY 24 Year to Date as of 8/31/2024
Beginning Balance : 9/01/2023		\$ 101,766.48
Increases:		
(1) License Plate Revenue Received	\$ 685.66	\$ 6,436.75
Interest	\$ 178.44	\$ 2,056.00
Total Increases	\$ 864.10	\$ 110,259.23
Reductions:		
Expenditures - Appropriated	\$ -	\$ -
	-	-
Total Reductions	\$ -	\$ -
Ending Balance: 8/31/2024		\$ 110,259.23

Note:

Balance forward from 2023 License Plate \$101,766.48

Cancer Prevention and Research Institute of Texas

Appropriated Receipts - 666

As of August 31, 2024

	<u>8/01/2024- 8/31/2024</u>	<u>AY 24 Year to Date as of 8/31/2024</u>
<u>Beginning Balance : 9/01/2023</u>		\$ 243,044.65
Increases:		
(1) Product Development Application Fees Received	\$ 500.00	\$ 29,500.00
(2) Conference Registration Fees	\$ -	\$ 84,640.00
(3) Conference Registration Fees-Credit Card	\$ -	\$ 1,761.70
Total Increases	<u>\$ 500.00</u>	<u>\$ 115,901.70</u>
Reductions:		
Conference Expenditures - Appropriated	\$ -	\$ (242,131.00)
Credit Card Fees Expended	\$ -	\$ (1,761.70)
Refund-Application Fees	\$ -	\$ -
Legal Services Expenses (Application Fees)	\$ (85,312.50)	\$ (85,312.50)
Total Reductions	<u>\$ (85,312.50)</u>	<u>\$ (329,205.20)</u>
<u>Ending Balance: 8/31/2024</u>		<u><u>\$ 29,741.15</u></u>

Forward balance for FY 2022 is \$55,246.90
 Application Fees
 Conference Fee for FY 2023 is \$187,797.75

Cancer Prevention and Research Institute of Texas
Interest & Sinking Fund Account - 5168
As of August 31, 2024

	<u>8/01/2024- 8/31/2024</u>	<u>AY 24 Year to Date as of 8/31/2024</u>
<u>Beginning Balance : 9/01/2023</u>		\$ 6,390,606.01
Increases:		
(1) Revenue Sharing / Royalties	\$ 263,234.81	\$ 842,448.12
	\$ -	\$ -
Total Increases	<u>\$ 263,234.81</u>	<u>\$ 7,233,054.13</u>
Reductions:		
Expenditures - Appropriated	\$ -	\$ -
	\$ -	\$ -
	\$ -	\$ -
Total Reductions	<u>\$ -</u>	<u>\$ -</u>
<u>Ending Balance: 8/31/2024</u>		<u><u>\$ 7,233,054.13</u></u>

Balance forward from FY 2023 is \$6,390,606.01